CWP
TEVA icon

Concord Wealth Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Concord Wealth Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-476
Closed -$4.86K – 1011
2023
Q3 		$4.86K Buy
+476
New +$4.43K ﹤0.01% 723

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Concord Wealth Partners's TEVA Position: Q4 2023 in Review

Concord Wealth Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 476 shares — an estimated $4.86K sold.

Concord Wealth Partners first reported a position in TEVA in Q3 2023 and held it in 1 quarter. The position peaked at $4.86K in Q3 2023. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Concord Wealth Partners reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Concord Wealth Partners sold 476 Teva Pharmaceuticals shares in Q4 2023, an estimated $4.86K.
  • Concord Wealth Partners first reported a position in Teva Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Concord Wealth Partners's Teva Pharmaceuticals position peaked at $4.86K in Q3 2023.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Concord Wealth Partners's 13F filing for Q4 2023, filed 6 Feb 2024.